We use cookies to understand how you use our site and to improve your experience.
This includes personalizing content and advertising.
By pressing "Accept All" or closing out of this banner, you consent to the use of all cookies and similar technologies and the sharing of information they collect with third parties.
You can reject marketing cookies by pressing "Deny Optional," but we still use essential, performance, and functional cookies.
In addition, whether you "Accept All," Deny Optional," click the X or otherwise continue to use the site, you accept our Privacy Policy and Terms of Service, revised from time to time.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
Ahead of Alcon (ALC) Q1 Earnings: Get Ready With Wall Street Estimates for Key Metrics
Read MoreHide Full Article
Wall Street analysts expect Alcon (ALC - Free Report) to post quarterly earnings of $0.76 per share in its upcoming report, which indicates a year-over-year decline of 2.6%. Revenues are expected to be $2.51 billion, up 2.7% from the year-ago quarter.
Over the last 30 days, there has been no revision in the consensus EPS estimate for the quarter. This signifies the covering analysts' collective reconsideration of their initial forecasts over the course of this timeframe.
Ahead of a company's earnings disclosure, it is crucial to give due consideration to changes in earnings estimates. These revisions serve as a noteworthy factor in predicting potential investor reactions to the stock. Numerous empirical studies consistently demonstrate a strong relationship between trends in earnings estimate revision and the short-term price performance of a stock.
While investors typically use consensus earnings and revenue estimates as indicators of quarterly business performance, exploring analysts' projections for specific key metrics can offer valuable insights.
That said, let's delve into the average estimates of some Alcon metrics that Wall Street analysts commonly model and monitor.
The collective assessment of analysts points to an estimated 'Net Sales- Total Surgical' of $1.38 billion. The estimate suggests a change of +2.8% year over year.
The average prediction of analysts places 'Net Sales- Total Vision care' at $1.14 billion. The estimate indicates a year-over-year change of +2.7%.
Analysts forecast 'Net Sales- Total Surgical- Consumables' to reach $717.01 million. The estimate points to a change of +4.5% from the year-ago quarter.
According to the collective judgment of analysts, 'Net Sales- Total Surgical- Equipment/other' should come in at $223.04 million. The estimate indicates a change of +1.8% from the prior-year quarter.
The combined assessment of analysts suggests that 'Net Sales- Total Vision Care- Contact lenses' will likely reach $693.41 million. The estimate indicates a change of +3.3% from the prior-year quarter.
Analysts predict that the 'Net Sales- Total Vision Care- Ocular health' will reach $441.87 million. The estimate indicates a year-over-year change of +1.6%.
The consensus among analysts is that 'Net Sales- Total Surgical- Implantables' will reach $435.74 million. The estimate indicates a change of +0.6% from the prior-year quarter.
The consensus estimate for 'Revenues- Other revenues' stands at $17.50 million. The estimate points to a change of +16.7% from the year-ago quarter.
It is projected by analysts that the 'Net sales by region- International' will reach $1.39 billion. The estimate indicates a change of +7.4% from the prior-year quarter.
Shares of Alcon have experienced a change of +6.8% in the past month compared to the +11.3% move of the Zacks S&P 500 composite. With a Zacks Rank #3 (Hold), ALC is expected to mirror the overall market performance in the near future. You can see the complete list of today's Zacks Rank #1 (Strong Buy) stocks here >>>>
See More Zacks Research for These Tickers
Normally $25 each - click below to receive one report FREE:
Image: Bigstock
Ahead of Alcon (ALC) Q1 Earnings: Get Ready With Wall Street Estimates for Key Metrics
Wall Street analysts expect Alcon (ALC - Free Report) to post quarterly earnings of $0.76 per share in its upcoming report, which indicates a year-over-year decline of 2.6%. Revenues are expected to be $2.51 billion, up 2.7% from the year-ago quarter.
Over the last 30 days, there has been no revision in the consensus EPS estimate for the quarter. This signifies the covering analysts' collective reconsideration of their initial forecasts over the course of this timeframe.
Ahead of a company's earnings disclosure, it is crucial to give due consideration to changes in earnings estimates. These revisions serve as a noteworthy factor in predicting potential investor reactions to the stock. Numerous empirical studies consistently demonstrate a strong relationship between trends in earnings estimate revision and the short-term price performance of a stock.
While investors typically use consensus earnings and revenue estimates as indicators of quarterly business performance, exploring analysts' projections for specific key metrics can offer valuable insights.
That said, let's delve into the average estimates of some Alcon metrics that Wall Street analysts commonly model and monitor.
The collective assessment of analysts points to an estimated 'Net Sales- Total Surgical' of $1.38 billion. The estimate suggests a change of +2.8% year over year.
The average prediction of analysts places 'Net Sales- Total Vision care' at $1.14 billion. The estimate indicates a year-over-year change of +2.7%.
Analysts forecast 'Net Sales- Total Surgical- Consumables' to reach $717.01 million. The estimate points to a change of +4.5% from the year-ago quarter.
According to the collective judgment of analysts, 'Net Sales- Total Surgical- Equipment/other' should come in at $223.04 million. The estimate indicates a change of +1.8% from the prior-year quarter.
The combined assessment of analysts suggests that 'Net Sales- Total Vision Care- Contact lenses' will likely reach $693.41 million. The estimate indicates a change of +3.3% from the prior-year quarter.
Analysts predict that the 'Net Sales- Total Vision Care- Ocular health' will reach $441.87 million. The estimate indicates a year-over-year change of +1.6%.
The consensus among analysts is that 'Net Sales- Total Surgical- Implantables' will reach $435.74 million. The estimate indicates a change of +0.6% from the prior-year quarter.
The consensus estimate for 'Revenues- Other revenues' stands at $17.50 million. The estimate points to a change of +16.7% from the year-ago quarter.
It is projected by analysts that the 'Net sales by region- International' will reach $1.39 billion. The estimate indicates a change of +7.4% from the prior-year quarter.
View all Key Company Metrics for Alcon here>>>
Shares of Alcon have experienced a change of +6.8% in the past month compared to the +11.3% move of the Zacks S&P 500 composite. With a Zacks Rank #3 (Hold), ALC is expected to mirror the overall market performance in the near future. You can see the complete list of today's Zacks Rank #1 (Strong Buy) stocks here >>>>